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There is an increasing body of evidence suggesting that altered vascular permeability may
be an important component of the pathogenesis of acute mountain sickness (AMS).
Vascular endothelial growth factor (VEGF) is a potent permeability factor subject to
hypoxic regulation but its role in the pathogenesis of AMS is yet to be defined. We
examined the relationship between plasma VEGF and AMS on ascent to high altitude and
subsequent acclimatisation.
Thirty-eight healthy lowlanders (median age 21, range 18–31) flew to La Paz, Bolivia
(3650m) on the Apex 2 research expedition. After 4–5 days acclimatisation, they ascended
by vehicle over 90min to the Chacaltaya laboratory (5200m). We measured plasma VEGF in
venous blood at sea level and at 6 h and 3 and 7 days at 5200m. AMS was scored using the
Lake Louise consensus system.
Using serial measurement of plasma VEGF at 5200m, following partial acclimatisation at
3650m, we demonstrated a highly significant change in VEGF levels (Po0.0005) with a rise
in VEGF in approximately 80% of subjects by day 7 at 5200m. We found no evidence of an
association between AMS and change in VEGF levels on ascent to either 3650 or 5200m.
We provide novel data of change in plasma VEGF levels during acclimatisation to high
altitude, but our results do not support the hypothesis that circulating unbound VEGF is an
important component of the pathogenesis of AMS.
& 2006 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
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Despite an increasing number of visitors to high altitudes,
much is still unknown regarding the pathophysiology and
treatment of acute mountain sickness (AMS) and the
potentially fatal conditions high-altitude pulmonary oedema
(HAPE) and high-altitude cerebral oedema (HACE). AMS is a
common condition that follows rapid ascent to high altitude
(greater than 2500m) and is characterised by a range of
symptoms including headache, insomnia, dizziness and
gastrointestinal upset.1 It has been proposed that AMS and
HACE form part of the spectrum of illness caused by
vasogenic cerebral oedema and raised intracranial pres-
sure.1–3 Likely underlying mechanisms of cerebral oedema
at high altitude include elevated cerebral capillary pres-
sure, impaired cerebral autoregulation, free radical-
mediated damage to the blood–brain barrier and alteration
in blood–brain barrier permeability through various hypoxia-
regulated mediators.2
One such mediator is vascular endothelial growth factor
(VEGF), shown to be significantly upregulated in the
presence of hypoxia in rat lungs and tumour cell lines4–6
through transcription factor hypoxia inducible factor-1
(HIF-1).7 As well as a powerful angiogenic and endothelial-
cell-specific mitogen, VEGF is a potent permeability
factor expressed in most tissues including the lung and
brain.8,9 Alternative splicing of exons six and seven
of the VEGF mRNA produces six isoforms.10 VEGF 121, 145
and 165 are all soluble products whereas VEGF 183, 189
and 206 remain cell-associated.
11 Hypoxia-induced cerebral
oedema in a mouse model can be attenuated by adminis-
tration of a VEGF-neutralising antibody12 and it has there-
fore been proposed that VEGF alters blood–brain barrier
permeability, thus contributing to the development of brain
swelling and oedema and thus symptomatic AMS and
HACE.1,3,13,14
Three studies have previously investigated the relation-
ship between VEGF and AMS, but no consistent relationship
has been found.15–17 However, meaningful comparison is
difficult given the differences in research methods and the
definitions of AMS used. For example, Maloney et al.15 did
not use a standardised ascent profile and defined AMS by
means of a Lake Louise self-assessment score of X2; in
contrast, Walter et al.16 defined AMS as Lake Louise score of
X5. These studies also generated conflicting data regarding
the response of VEGF to high altitude hypoxia.15–17 Data
from Walter et al. suggest that there is an increase in plasma
VEGF on arrival at high altitude while Tissot van Patot et al.
found a significant increase only in subjects diagnosed with
AMS.16,17 None of these studies made serial measurements
at altitude.15–17
Several studies have investigated the effect of hypoxia-
induced VEGF expression over time.14,18,19 Kuo et al.
described an increase in rat brain VEGF mRNA and protein
levels on exposure to hypoxia. Interestingly, although VEGF
mRNA and protein expression increased during days 1 and 2,
mRNA levels were reduced by day 4 and had returned to
baseline levels by day 7. In contrast, tissue protein levels
exhibited a biphasic response falling on day 4 but rising
again on day 7.18
Given the above experimental findings we sought to
gather novel data on the response of plasma VEGF expressionto prolonged hypoxia by taking serial VEGF samples in a
cohort of healthy lowlanders. We also aimed to study the
relationship between plasma VEGF concentration and oxygen
saturation (SpO2), pulmonary artery systolic pressure (PASP)
and AMS following controlled ascent to high altitude
(5200m).
Materials and methods
Subjects and study design
Forty-two healthy lowland subjects participating in the Apex
2 expedition (Altitude Physiology Expeditions) and residing
at an altitude less than 50m were enrolled.20 The study was
approved by the Lothian Research Ethics Committee. All
subjects were in the placebo arm of a study investigating
drug treatments at high altitude. One subject was excluded
with HAPE and samples could not be obtained for 3 others.
Of the 38 remaining (24 males, median age 22, range 18 to
25 and 14 females, median age 20, range 19–28), 6 were
evacuated with symptoms of AMS at various points from day
1 onwards at 5200m. Data were included up to the time of
evacuation.
Subjects were flown from Britain to La Paz, Bolivia
(3650m) and after 4 or 5 days acclimatisation they ascended
by road, over a period of 90min, to the Chacaltaya
laboratory (5200m), where they stayed for 8 days (Fig. 1).
Venous blood samples were taken in EDTA at five time-
points: at sea-level prior to departure, at 5200m on day 1
(within 6 h of arrival), day 3 and 7, and again at sea-level at
least 6 weeks after return to the UK. Venous blood was
immediately centrifuged at 3000g for 10min (Labofuge 200,
Kendro Laboratory Services, Herts, UK). Plasma aliquots
were transported on dry ice by specialist international
courier and stored at 80 1C prior to analysis.
Assessment of AMS score, SpO2 and pulmonary
artery systolic pressure
On each evening of the expedition subjects completed a
Lake Louise AMS self-assessment score-sheet. As per Lake
Louise consensus scoring, AMS was defined as a total score of
X3 with the presence of headache.21 At the same time,
peripheral oxygen saturation (SpO2) was measured using
digital pulse oximetry (Nellcors N-20PA, USA). Echocardio-
graphy was performed on day 1, 3 and 7 at 5200m within 3 h
of venous blood sampling using a portable real-time phased-
array echocardiographic scanner (Acuson Cypress, Siemens
Medical Solutions, UK) operated by an experienced cardiol-
ogist. PASP was estimated by adding the clinically deter-
mined jugular venous pressure to the right ventricular to
right atrial pressure gradient. The gradient was calculated
using the modified Bernoulli equation.22
ELISA
Concentrations of the predominant VEGF isoforms, VEGF121
and VEGF165, in plasma obtained from the subjects were
measured by sandwich ELISA (Quantikines Human VEGF
Immunoassay, DVE00, R&D systems, MN, USA). In brief,
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Figure 1 Ascent profile of the Apex 2 expedition. Days on which VEGF samples were taken are indicated by filled boxes. Tick marks
on the x-axis represent 1 day and breaks indicate periods of longer than 1 day.
Plasma vascular endothelial growth factor 589100 ml of undiluted plasma were incubated for 1 h at
room temperature in a 96-well plate coated with mono-
clonal VEGF antibody. Following three washes polyclonal
detection antibody was added with substrate solution
subsequently used. Absorbance was measured at 750 nm in
a microplate reader. For standardisation, serial dilutions of
recombinant hVEGF (121 and 165) were assayed simulta-
neously. Levels below the lower limit of detection of this
assay (3.9 pmol/l) were classed as undetectable and
ascribed a plasma VEGF concentration of 0 pmol/l. Two
individuals did not have detectable VEGF in any of their
samples and a further 9 individuals had one or more samples
in which VEGF was undetectable. Measurements were
performed in triplicate and results were excluded as
unreliable where an upper limit of 20% in the coefficient
of variation was exceeded. Nine measurements were
excluded in this way.Statistics
A significance level of 5% was assumed throughout for all
statistical analyses.
The variation in % change from sea-level baseline of VEGF,
SpO2 and PASP over the four time-points (encompassing
ascent and acclimatisation to high altitude, and return to
sea level) was assessed using the Friedman test. In turn, the
Wilcoxon matched pairs signed ranks test (with a correction
for multiple comparisons using the Simes method)23 was
used in performing the corresponding pairwise comparisons
over stages of the expedition for each of the above
variables. To identify possible discrepancies across gender,
similar tests were performed with VEGF levels for males and
females separately.
The Mann–Whitney U-test was used to compare percen-
tage change from sea-level baseline VEGF levels between
those who did and did not develop AMS on day 2 at 3650m or
day 2 at 5200m. The percentage change in VEGF level
from pre-expedition sea level to day 1 at 5200m was
calculated and based on careful examination of the
distributions for these data for positive and negative AMS
cases separately, subjects were classified into the followingfour categories according to the magnitude of percentage
change: ‘200 o % change o 0’, ‘% change ¼ 0’, ‘0 o %
change o 200’, ‘% change 4 300’. No subjects had a %
change in VEGF of between 200 and 300. Fisher’s
exact test was used to assess the relationship between
these categories and AMS status on day 2 at 5200m and
on day 2 at 3650m. These time points were chosen
because, consistent with previous work, peak prevalence
of AMS occurred on day 2 following ascent.21 For complete-
ness, and on account of the small sample size, change in
VEGF levels from sea level to day 1 at 5200m was
also examined by classifying the VEGF percentage
change into the broader categories ‘% change p 0’ and ‘%
change 4 0’. The resultant data were examined using the
chi-squared test of association and, where appropriate,
Fisher’s Exact test.
Relationships between continuous variables were exam-
ined by means of individual scatter-plots and where these
graphs were suggestive of at least a very weak linear trend,
Pearson correlation coefficients (PCCs) were calculated as a
measure of the strength of the corresponding linear trends.
The relationships examined at the univariate level by these
methods included:(1) AMS score for day 2 at 5200m against age and
percentage changes in VEGF, PASP and SpO2 level from
pre-expedition sea level to day 1 at 5200m.(2) AMS score for day 2 at 3650m against age and
percentage changes in VEGF, PASP and SpO2 level from
pre-expedition sea level to day 1 at 5200m.(3) AMS score for day 1 at 5200m against age and
percentage changes in VEGF, PASP and SpO2 level from
pre-expedition sea level to day 1 at 5200m.(4) As for (3) but with all measurements, including AMS
scores, taken at day 3 rather than at day 1.(5) As for (3) but with all measurements, including AMS
scores, taken at day 7 rather than at day 1.During this exploratory process, two criteria for identifica-
tion of a potential factor for inclusion in a future
multiple regression analysis were that the value of the
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association was consistent with the behaviour exhibited in
the corresponding scatter-plot. Further, it was required that
on entry to the linear regression model the factor in
question made a significant contribution in explaining the
variability in AMS scores for the corresponding regression
analysis at the univariate level (as demonstrated by the
related F-test). According to these non-stringent criteria, at
most one continuous factor was retained per dependent
variable. In order to assess the effect of possible confound-
ing caused by gender differences, hierarchical multiple
regression analyses were performed for those variables
which survived the screening process. Where the corre-
sponding F-test revealed that the inclusion of gender made a
significant improvement to the predictive value of the
model, Pearson’s partial correlation coefficient (controlling
for gender) was assumed as the more accurate measure of
the strength of the linear relationship between the
continuous factor in the model and the corresponding
response variable for VEGF.
Results
Distribution of sea-level VEGF within sample group
Baseline VEGF expression ranged from 0 to 408 pmol/l
(median ¼ 30.3 pmol/l, n ¼ 36). Nineteen individuals ex-
pressed a VEGF level less than 50 pmol/l at sea level and0
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Figure 2 Plasma VEGF levels for each individual subject. The y-axi
see trends in the population who expressed lower levels of VEGF. S
various points from day 1 onwards at 5200m. Data were included u8 of these had undetectable baseline VEGF concentrations
(Fig. 2).
Variation in plasma VEGF levels
The non-parametric tests to examine overall changes in VEGF
over ascent and acclimatisation revealed a highly significant
association between VEGF and stage of expedition (ascent,
acclimatisation and return to sea level) (Po0.0005). VEGF
levels are available for 29 subjects on both the pre-expedition
sea-level sample and day 7 at 5200m; of these, 24 subjects
demonstrated a rise in VEGF at high altitude. Likewise, all
subjects had lower VEGF levels on return to sea level, than on
day 7 at 5200m (Fig. 2). Medians and corresponding ranges for
VEGF at each stage of the expedition are provided in Table 1.
The corresponding results for the pairwise comparisons are
summarised in Table 2, showing a highly significant difference
between both sea-level samples and day 7 at 5200m.
Separate analysis of males and females showed a significant
association overall between stage of expedition and VEGF
levels for both sexes, but the association was stronger in
females (Po0.0005) than males ðP ¼ 0:02Þ.
Plasma VEGF and AMS
Plasma VEGF level at sea level before the expedition did
not predict susceptibility to AMS on ascent to high
altitude (Fig. 3). Furthermore, there was no evidence ofPre-expedition
sea level
ay 3 at
200 m
Day 7 at
5200 m
s is divided into two separate scales in order to make it easier to
ix of the 38 subjects were evacuated with symptoms of AMS at
p to the time of evacuation.
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Table 1 Summary statistics for plasma VEGF, oxygen saturation (SpO2), pulmonary artery systolic pressure (PASP) and
prevalence of acute mountain sickness (AMS) for different stages of the expedition.
Sea level Day 1 Day 3 Day 7 Sea levely
5200m 5200m 5200m
VEGF (pmol/l) 30.3 43.0 45.3 39.0 42.2
Range (min, max) (0.0, 408.3) (0.0, 409.7) (0.0, 420.4) (0.0, 450.9) (0.0, 439.4)
n number 36 37 32 31 31
SpO2 (%) 99.0 76.5 74.5 78.5
z
Range (min, max) (95.0, 100.0) (60.0, 90.0) (63.0, 81.0) (59.0, 86.0)
n number 32 34 24 26
PASP (mmHg) 17.0 31.5 31.0 33.0 22.0
Range (min, max) (8.0, 27.5) (21.0, 67.0) (22.0, 55.0) (22.0, 43.0) (17.0, 30.0)
n number 30 32 25 23 24
Prevalence of 0 59.5 51.5 12.5 z
AMS (%) (SE) (0.0) (8.1) (8.7) (5.8)
n number 38 37 33 32
Six of the 38 subjects were evacuated with symptoms of AMS at various points from day 1 onwards at 5200m. Data were included up to
the time of evacuation.
Pre-expedition sea level.
yPost-expedition sea level.
zData not available.
Table 2 Comparisons of plasma VEGF levels between
all sample points using paired data.
Categories compared P-value
Sea level vs. Day 1 0.767
Sea level vs. Day 3 0.194
Sea level vs. Day 7 0.003
Sea level vs. Sea levely 0.005
Day 1 vs. Day 3 0.032
Day 1 vs. Day 7 o0.0005
Day 1 vs. Sea levely 0.003
Day 3 vs. Day 7 0.017
Day 3 vs. Sea levely 0.005
Day 7 vs. Sea levely o0.0005
The pairwise comparisons represented were performed using
the Wilcoxon matched pairs signed ranks test and the P-
values obtained on application of the Simes method23 to
correct for multiple comparisons.
‘Day 1’, ‘Day 3’ and ‘Day 7’ denote time spent at 5200m.
Pre-expedition sea level.
yPost-expedition sea level.
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Figure 3 Baseline (sea level) plasma VEGF levels in AMS
positive and AMS negative subjects. AMS positive individuals are
those with a Lake Louise score 43 on day 2 at 5200m. AMS is
most likely to develop on the day following arrival at altitude
and therefore we chose to use AMS data from day 2 at 5200m to
examine the relationship between sea-level VEGF expression
and AMS. Data were available for 34 subjects; VEGF levels for 2
subjects were excluded through the quality control and AMS
data were not available for 2 subjects who had been evacuated
by day 2 at 5200m.
Plasma vascular endothelial growth factor 591an association between AMS status and VEGF category on
ascent to high altitude. This was true regardless of whether
the reference point for AMS status was day 2 at 5200m or
day 2 at 3650m (Table 3). Similar analyses performed
defining AMS as a Lake Louise score X4 had a negligible
effect on the test results.
The comprehensive multivariate analysis described above
did not show any evidence of an association between plasmaVEGF and AMS scores. The scatter-plots and linear regression
analyses demonstrated no evidence for any association
between AMS score and percentage change in VEGF level
from baseline. In the main, scatter-plots exhibited random
behaviour.
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Table 3 Tests for association between AMS category and percentage change in VEGF.
Stage of expedition for diagnosis of AMS Classification assumed for % change in VEGF P-value
Day 2 at 5200m Classification 1 0.207
Day 2 at 5200m Classification 2 0.765
Day 2 at 3650m Classification 1 0.840
Day 2 at 3650m Classification 2 1.000
Analyses were performed comparing pre-expedition sea level to day 1 at 5200m using the VEGF categories ‘200o% changeo0’, ‘%
change ¼ 0’ and ‘0o% changeo200’, ‘% change4300’ (classification 1) and using the VEGF categories ‘% changep0’ and ‘% change
40’ (classification 2). AMS is most likely to develop on the day following arrival at altitude and therefore we chose to use AMS data
from day 2 at 3650m and day 2 at 5200m to examine the relationship between sea level VEGF expression and AMS category. Data were
available for 35 subjects at 3650m and 33 subjects at 5200m; % change in VEGF was not available for 3 subjects and AMS data were not
available for 2 subjects who had been evacuated by day 2 at 5200m.
Indicates those instances where Fisher’s exact test was used.
D.A. Dorward et al.592Variation in oxygen saturation and pulmonary artery
systolic pressure
Consistent with previous results, the median SpO2 level fell
following ascent and PASP increased significantly. Explora-
tory analyses using scatter plots were not indicative of any
association between VEGF level and SpO2 or PASP.
Discussion
In this study we have examined the relationship between
plasma VEGF and AMS on ascent to high altitude and
subsequent acclimatisation.
Baseline VEGF levels
Among the 38 individuals studied, we found significant
variation in baseline plasma VEGF levels (0–408 pmol/l). The
upper limit of our range is 10-fold higher than that reported
in healthy controls by Thickett et al.24 but others have
reported plasma VEGF ranges similar to ours.15,17,25 It is
unlikely that the high upper limit of baseline VEGF
expression in our study is due to platelet-derived VEGF
since plasma was separated at a high centrifugal force
(3000g).
VEGF levels on ascent to altitude
VEGF levels changed significantly over the course of ascent
and acclimatisation to high altitude, and a large majority
(80%) of subjects demonstrated an increase in VEGF levels
during acclimatisation to high altitude.
Hypoxia-induced upregulation of VEGF, both at a tran-
scriptional and protein level in vitro, and in the circulation
in vivo, in conditions characterised by systemic hypoxia such
as acute respiratory distress syndrome (ARDS) is well
documented.11,24 However, serum VEGF did not increase in
a study of HAPE-susceptible individuals following 24 h
exposure to hypobaric conditions equivalent to 4000m.26
Previous studies described an increase in VEGF levels
immediately following ascent16,17 but we demonstrate thatin the majority of subjects there was a rise in VEGF levels by
day 7 at 5200m. It is possible that an immediate increase in
VEGF levels following ascent to 5200m was missed because
we allowed subjects to partially acclimatise to 3650m. At
the post-expedition sea-level sample point, the failure of
VEGF levels to return to pre-expedition values was un-
expected. This suggests that exposure to high altitude may
have caused some more prolonged alteration in the
regulation or production of VEGF.VEGF and AMS
Accumulation of in vitro data and animal studies suggested a
role for the HIF-1 regulated cytokine VEGF in the pathogen-
esis of AMS and HACE.12,13,14 This hypothesis is supported by
the observation that dexamethasone, which is effective
both in the prophylaxis and treatment of AMS,27,28 blocks
hypoxic induction of VEGF mRNA.29 Previous publications
found no significant difference in plasma VEGF between
individuals with AMS and those without.15,16 One controlled
study involving 5 subjects suggested that VEGF change on
ascent to altitude may be predictive of the onset of AMS.15
Our results do not support this hypothesis (Table 3), or the
hypothesis that baseline VEGF levels predict AMS suscept-
ibility (Fig. 3).
Recently Tissot van Patot et al. described lower levels of
soluble VEGF receptor Flt-1 (sFlt-1) combined with a
significant increase in plasma VEGF in individuals with
AMS.17 The apparent discrepancy between this study and
our work may be attributable to small sample size,
individual variability and different ascent profile, including
the altitude at which measurements were made. It should
also be noted that subjects in their study did not reside at
sea level but at altitudes of between 1370 and 1645m.17 As
a soluble factor under hypoxic regulation, sFlt-1 acts to
sequester unbound VEGF from the circulation, therefore
preventing its interaction with the endothelium-bound
receptors that mediate its effects upon endothelial function
and vascular permeability.30 A hypoxic-mediated increase in
sFlt-1 could therefore counteract an increase in VEGF
production preventing it from mediating an effect. In those
individuals with AMS a lower level of sFlt-1 may allow
ARTICLE IN PRESS
Plasma vascular endothelial growth factor 593unbound VEGF to affect blood brain barrier permeability and
contribute to the development of AMS. The importance of
the cytokine in the development of high-altitude illness is
therefore uncertain. Furthermore, recent data from T2
weighted magnetic resonance imaging (MRI) studies suggests
that AMS may not be caused by vasogenic oedema as
previously thought.31,32
The role of inflammatory mediators in the pathogenesis
of high-altitude illness is currently under scrutiny.
Swenson et al. proposed early HAPE to be due to non-
inflammatory breach of the alveolar-capillary barrier33 given
that initiation of HAPE is associated with an increase in
pulmonary capillary pressure.34 Previous studies have
proposed a role for VEGF in the pathogenesis of hypoxic
pulmonary hypertension.4,35 However, our findings show no
clear relationship between systemic VEGF and PASP on days
1, 3 and 7 at 5200m.
Compartmentalisation of VEGF expression
Whilst there is no apparent relationship between plasma
VEGF and AMS, the findings of this study as well as previous
research do not preclude the involvement of VEGF in the
pathogenesis of high-altitude illness. In a murine model of
normobaric hypoxia-induced cerebral oedema, systemically
delivered anti-VEGF neutralising antibody attenuated vas-
cular leak. Brain tissue expression, but not plasma levels of
VEGF were increased following the hypoxic insult.12 Hypox-
ia-induced VEGF production by brain-derived microvascular
endothelial cells (BMEC) has been shown to act in an
autocrine fashion in the regulation of blood–brain barrier
permeability36 and it is likely that local tissue or compart-
mentalised expression of VEGF is critical in mediating
oedema.12,37 A similar concept applies to the lung in which
there is significant compartmentalisation of VEGF to the
alveolar surface relative to the vascular compartment. This
difference in distribution is attributable to both the
production of VEGF in alveolar type II epithelial cells and a
tight epithelial barrier preventing diffusion to the endothe-
lial surface.38 Interestingly, VEGF levels in bronchoalveolar
lavage fluid (BALF) of patients with HAPE have been
shown to be significantly reduced relative to healthy
control subjects.39 In ARDS a reduction in BALF VEGF is
associated with a significant increase in circulating plasma
VEGF, potentially due to loss of alveolar/epithelial barrier
integrity.24,40
Limitations of the study
Our study had several limitations. Firstly, it was not possible
to gather blood samples from subjects on day 2 at 5200m or
whilst at the intermediate altitude of 3650m. We may
therefore have missed an early rise in plasma VEGF on initial
ascent to 3650m or a change on day 2 at 5200m, the day on
which there was the highest prevalence of AMS.
By spending 4 days at 3650m, subjects were able to
partially acclimatise at this altitude and this may have
reduced the impact of further ascent on VEGF expression.
However, our study may more closely simulate the behaviour
of many climbers because of the inclusion of a period of pre-
acclimatisation before ascent to a summit. We believe thatour ascent profile provides useful information on the role of
VEGF in AMS, as despite this pre-acclimatisation ascent to
5200m caused a sizeable fall in inspired oxygen fraction and
provoked a high incidence of AMS.
Secondly, it has been suggested that measurement of
absolute VEGF levels ought to quantify not only free VEGF
levels but also its complexes with sFlt-1, the soluble VEGF
receptor sKDR, and placenta growth factor (PLGF).41 At
present, assays of these VEGF-complexes are technically
demanding and not commercially available. However, as
described previously, sFlt-1 levels may prove to be asso-
ciated with AMS susceptibility.
Thirdly, on account of the size of our study cohort and the
number of exclusions, it is not possible to exclude a
relationship between unbound VEGF and AMS.
Finally, meaningful comparison with previous studies is
hindered by different ascent profiles, final altitude of
acclimatisation, the definition of AMS and subject demo-
graphics. Although our cohort was younger than in
previous studies of VEGF at altitude, our study contributes
novel data to this area by performing serial VEGF
measurements following non-exertional ascent to very high
altitude.
Conclusion
We have demonstrated a significant change in VEGF levels
during acclimatisation to high altitude. Despite the popular
hypothesis that hypoxic induction of VEGF resulting in
alterations to blood–brain barrier permeability may lead
to AMS and HACE, we found no evidence of a relationship
between changes in unbound plasma VEGF levels and AMS.
Nevertheless the possibility remains that at a cellular level,
VEGF contributes to the pathogenesis of high–altitude illness
through autocrine and paracrine effects at the blood–brain
barrier.
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